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Abstract
Background: Advanced glycation end products (AGEs) and their receptor RAGE emerge as important pathogenic
contributors in colorectal carcinogenesis. However, their relationship to the detoxification enzyme Glyoxalase
(GLO)-I and Adiponectin receptors (AdipoR1, AdipoR2) in colorectal carcinoma (CRC) is currently understudied.
In the present study, we investigated the expression levels of the above molecules in CRC compared to adjacent
non-tumoral tissue and their potential correlation with clinicopathological characteristics and patients’ survival.
Methods: We analyzed the immunohistochemical expression of AGE, RAGE, GLO-1, AdipoR1 and AdipoR2 in 133
primary CRC cases, focusing on GLO-I. The tumour MSI status was further assessed in mucinous carcinomas.
Western immunoblotting was employed for validation of immunohistochemical data in normal and tumoral tissues
as well in three CRC cell lines. An independent set of 55 patients was also used to validate the results of univariate
survival analysis regarding GLO-I.
Results: CRC tissue showed higher intensity of both AGE and RAGE expression compared with normal colonic
mucosa which was negative for GLO-I in most cases (78 %). Western immunoblotting confirmed AGE, RAGE and
GLO-I overexpression in tumoral tissue. GLO-I expression was directly related to RAGE and inversely related to AGE
immunolabeling. There was a trend towards higher expression of all markers (except for RAGE) in the subgroup of
mucinous carcinomas which, although of borderline significance, seemed to be more prominent for AdipoR1 and
AGE. Additionally, AGE, AdipoR1 and Adipo R2 expression was related to tumor grade, whereas GLO-1 and AdipoR1
to T-category. In survival analysis, AdipoR2 and GLO-I overexpression predicted shortened survival in the entire
cohort and in early stage cases, an effect which for GLO-I was reproduced in the validation cohort. Moreover,
GLO-I emerged as an independent prognosticator of adverse significance in the patients’ cohort.
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Conclusions: We herein provide novel evidence regarding the possible interactions between the components of
AGE-RAGE axis, GLO-I and adiponectin receptors in CRC. AGE and AdipoR1 are possibly involved in colorectal
carcinogenesis, whereas AdipoR2 and GLO-I emerged as novel independent prognostic biomarkers of adverse
significance for patients with early disease stage. Further studies are warranted to extend our observations and
investigate their potential therapeutic significance.
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Background
Colorectal cancer (CRC) is the third most common malig-
nancy in men and second in women, preceded by breast
cancer in the latter [1]. The risk for CRC is significantly
higher in obese and diabetic patients [2]. It is nowadays
evident that environmental factors, such as a high caloric
Western diet rich in fat, play an important role in the
pathogenesis of the disease. Accumulating data suggest
that insulin resistance, hyperglycemia and chronic inflam-
mation lead to carcinogenesis through interaction with
genetic characteristics, although the underlying molecular
pathways remain to be clarified [2].
Advanced glycation end products (AGEs) are highly
reactive molecules, formed endogenously or exogenously
when glucose or other reducing sugars react with amino
acids, nucleotide bases or fatty acids [3]. Endogenous
AGEs are produced during metabolic oxidative stress
and accumulate in tissues normally with age [4], their
production dramatically accelerated by hyperglycemia
[5]. High levels of exogenous AGEs, also known as
glycotoxins, are generated by contemporary methods of
cooking applying dry heat and high temperatures, bever-
ages and cigarette smoking [3]. Exogenous AGEs are
absorbed orally, thus directly influencing plasma concen-
trations and tissue deposition [6]. Excessive accumula-
tion of glycotoxins has been implicated in many
metabolic, degenerative and inflammatory disorders, as
well as cancer development.
AGEs exert their detrimental effects by forming cross-
links with adjacent extracellular matrix proteins, thus
reducing tissue flexibility [5]. Intracellular functions of
AGEs are mediated via binding to the receptor for
advanced glycation end products (RAGE), a transmem-
brane receptor and member of the immunoglobulin
protein family. RAGE has been identified in a variety of
cells and tissues [7] and is now considered a pattern
recognition receptor (PRR) with a broad spectrum of
ligands, including high-mobility group box-1 (HMGB1)
and S100 proteins [8]. RAGE activation initiates down-
stream signaling pathways which promote inflammation,
support cell survival, inhibit apoptosis and induce angio-
genesis, leading to tumor growth and invasion in an
inflammatory microenvironment [9]. Its expression has
been detected in various tumors including colorectal
carcinoma [10] and precancerous lesions such as
colon adenomas [11]. Data derived from in vitro stud-
ies and rat models indicate that RAGE is significantly
associated with CRC tumor development, progression
and metastasis [12].
AGEs cytotoxicity is attenuated by the endogenous
glyoxalase scavenging system [13]. Glyoxalase (GLO)-I
and GLO-II are ubiquitously expressed enzymes which
protect proteins, nucleotides and phospholipids from ad-
vanced glycation reactions by decreasing the levels of
AGEs precursors [14]. Tumor cells with a high glycolytic
rate benefit the most from the glyoxalase detoxification
system. GLO-I gene amplification and overexpression
has been identified in breast, lung, bladder, gastric and
several other carcinomas [15]. With respect to CRC,
amplification of GLO I is reported to be rare [15], al-
though earlier studies demonstrated a 2-fold increased
activity in tumor versus normal colonic epithelium [16].
Adiponectin, a peptide hormone produced exclusively
by adipose tissue and implicated in glucose metabolism,
appears to reduce insulin-resistance. Obese patients
exhibit lower adiponectin serum levels compared to in-
dividuals of normal weight [17], whereas epidemiologic
studies portray an inverse association between this
hormone’s levels and various types of cancer, including
CRC [18]. Adiponectin elicits its action through two
receptors, AdipoR1 and AdipoR2, partly differing in
distribution and potential functions [17]. Expression of
AdipoR1 and AdipoR2 has been detected in pancreatic
[19], gastric [20] and colon human carcinomas [21–25].
However, a few surveys dealing with CRC expression levels
in relation to patients’ clinicopathological parameters, have
resulted in inconclusive or controversial results.
Furthermore, adiponectin was found to be inversely
associated with AGE/RAGE serum ratio [26] and
similarly plasma levels of N-(carboxymethyl) lysine
(CML), a prominent type of AGE, correlated negatively
with adiponectin levels in overweight patients [27]. In
vitro experiments support a link between AGE and
adiponectin expression, implicating the anti-oxidative prop-
erty of the latter [28] and arguing in favor of its protective
effect on AGEs-induced endothelial dysfunction [27].
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Current data on the role of the AGE-RAGE axis in
CRC, particularly as related to GLO-I and AdipoR1or
AdipoR2 expression, is insufficient. The present study
was undertaken in an attempt to shed light upon the
potential correlation between expression of the above
molecules and clinicopathological characteristics, as well
as the survival of CRC patients. To this end, we analyzed
the expression of AdipoR1, AdipoR2, AGE, RAGE and
GLO-I, focusing on the latter, in a large series of CRC
patients with available clinicopathological characteristics
and follow up and validated our findings by western im-
munoblotting in fresh tissue from normal colonic mu-




This is a retrospective study performed on archival tis-
sue specimens from 133 cases of primary colorectal
adenocarcinoma, diagnosed between 2000 and 2010 at
the First Department of Pathology, University of Athens,
Medical School, the Department of Pathology, “Tzaneio”
General Hospital and the Department of Pathology,
“Agios Andreas” General Hospital. The protocol of the
study was approved by the University of Athens Bioeth-
ics Committee (PN 5106/2012) and follows the princi-
ples of the Declaration of Helsinki. Included were 61
men and 72 women with a median age of 70 years
(range 41–87 years). Informed consent was obtained
from all patients before their enrolment in the study.
None of the patients had received chemotherapy or radi-
ation before surgery.
All cases were reviewed by two experienced patholo-
gists (PK, SS) for the assessment of the degree of differ-
entiation, according to the latest World Health
Organization classification of colorectal carcinoma. In
order to assign a grade of differentiation in mucinous
carcinomas (19 cases), the tumour MSI status was evalu-
ated by both immunohistochemistry and molecular ana-
lyses. The nuclear expression levels of the respective
MMR proteins were evaluated, whereas in those cases in
which the immunohistochemical pattern could not
define the MSI status, the molecular profile of additional
MSI markers was identified (BAT25, BAT26, NR24,
BRAF) [29]. Cases lacking mismatch repair (MMR) pro-
tein expression and therefore exhibiting MSI (MSI-high,
MSI-H), were classified as low-grade carcinomas. On
the other hand, tumours which did not exhibit MSI
(MSI stable or MSI-low, MSS or MSI-L) were classified
as high-grade carcinomas. Patient’s cohort consisted of
22 well differentiated (grade I), 90 moderately differenti-
ated (grade II) and 21 poorly differentiated (grade III)
adenocarcinomas.
According to the 6th edition of the TNM classification
system, tumours were classified as stage I (n = 7 cases),
stage II (n = 52 cases), stage III (n = 53 cases) and stage
IV (n = 12 cases). In nine cases, corresponding to an
incision tumour biopsy, assessment of TNM classifica-
tion was not feasible. Patients’ clinicopathological
characteristics are summarised in Table 1.
By the time this study was undertaken, 35 patients had
died of their disease after a median survival of 19 months
Table 1 Demographic characteristics of patients included in the
study and validation cohort in this investigation
Study cohort Validation Cohort
Variable Value Value
Number of patients 133 55
Mean (range):
Patients age, years 70 (41–87) 74.5 (42–90)
Follow-up, months 44 (1–84) 26 (1–60)
n (%) n (%)
Gender:
Female 72 (54.13 %) 28 (50.91 %)
Male 61 (45.87 %) 27 (49.09 %)
Histological Grade
I 22 (16.54 %) 3 (5.45 %)
II 90 (67.67 %) 36 (65.45 %)
III 21 (15.79 %) 16 (29.09 %)
Tumor status
T1 11 (8.27 %) 2 (3.64 %)
T2 12 (9.02 %) 12 (21.82 %)
T3 87 (65.42 %) 33 (60.00 %)
T4 23 (17.29 %) 8 (14.55 %)
Nodal status
No 62 (46.62 %) 32 (58.18 %)
N1 36 (27.07 %) 15 (27.27 %)
N2 25 (18.79 %) 8(14.55 %)
Not available 10 (7.52 %) -
TNM stage
I 7 (5.26 %) 10 (18.18 %)
II 52 (39.09 %) 19 (34.55 %)
III 53 (39.86 %) 17 (30.91 %)
IV 12 (9.02 %) 9 (16.36 %)
Not available 9 (6.77 %) -
Tumor location
Right colon 54 (40.60 %) 21 (31.18 %)
Left colon 79 (59.40 %) 34 (61.82 %)
Histological type
Mucinous 19 (14.29 %) 5 (9.09 %)
Non-mucinous 114 (85.71 %) 50 (90.91 %)
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(range 1–57) and nine were lost to follow-up. The me-
dian follow-up for the remaining 89 patients was
56 months (range 12–84 months). Information regarding
recurrence was available in 119 patients, among which
27 had recurred.
Immunohistochemical analysis
Immunostaining for AGE, RAGE, Glyoxalase-I, Adipo-
nectin Receptor Type 1 and Adiponectin Receptor Type
2 was performed on freshly cut, paraffin-embedded
4 μm sections of formalin fixed tumour tissue which
were left to dry overnight at 37 °C using the two-step
peroxidase conjugated polymer technique (DAKO Envi-
sion kit, DAKO, Carpinteria, CA). For antigen retrieval,
tissue sections were treated in the microwave with so-
dium citrate buffer, pH 6.0, for 20 min. Sections were in-
cubated with the primary antibodies overnight at 4 °C,
except for the anti-Adiponectin Receptor Type 1 antibody,
where the incubation time was 60 min at 4 °C. Details on
the primary antibodies used are listed in Table 2. In
negative controls the primary antibody was substituted by
nonimmune serum.
Immunohistochemical evaluation was performed by
two pathologists (PK, PF), without knowledge of the
clinical information. For each antibody, the staining
distribution (cytoplasmic, nuclear, membranous, lu-
minal) as well as the staining pattern (diffuse or granu-
lar) was recorded. The percentage of positive neoplastic
cells as well as the intensity of staining (1: faint staining,
2: moderate staining, 3: intense staining) were evaluated
separately. Moderate staining was defined as equivalent
to that of adjacent lymphocytic aggregates. A Histo-
score (H-score) based on the percentage of stained neo-
plastic cells multiplied by staining intensity was calcu-
lated. Finally, in order to investigate any differences in
the expression of AGE, RAGE, AdipoR1 and AdipoR2
between the normal and neoplastic tissue, the extent
and the intensity of staining observed in the normal ad-
jacent colonic mucosa (in those cases in which it was
available) was also recorded.
Western immunoblotting
Protein extraction from two normal colon mucosa, 2
CRC neoplastic tissues and three colon carcinoma cell
lines (SW480, HT29, HCT116) was performed using ice-
cold RIPA lysis buffer (#9801, Cell Signaling Technol-
ogy) containing protease and phosphatase inhibitors
with the extra addition of PMSF (Sigma Aldrich). Brad-
ford assay (Bio-Rad) was used to assess protein concen-
tration in the extracts. Proteins were separated by SDS-
polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane (Porablot NCP, Macherey-
Nagel). Membranes were blocked for 1 h in room
temperature in Phosphate Buffered Saline Tween-20
(PBST) with 5 % non-fat milk. Subsequently, membranes
were incubated overnight at 4 °C with the following
primary antibodies: anti-AGE (Abcam, ab23722, dilution
1:1000), anti-RAGE (Santa Cruz Biotechnology, sc-8230,
dilution 1:200), anti-glyoxalase (GLO-I) (sc-133144,
dilution 1:200). Primary antibodies were diluted in PBST
containing 1 % non-fat milk. The membranes were then
incubated with the HRP - conjugated secondary anti-
bodies for 1 h in room temperature. Secondary anti-
bodies goat anti-rabbit IgG-HRP (12–348, Millipore)
and goat anti-mouse IgG-HRP (12–349, Millipore) di-
luted 1:2000 were used. The detection of the immunore-
active bands was performed with the SuperSignal
WestPico Chemiluminescent HRP Substrate kit (Thermo
Scientific). Relative protein amounts were evaluated by a
densitometric analysis using Image J software (La Jolla,
CA, USA) and normalized to the corresponding Actin
levels. All experiments have been performed at least
3 times and representative results of one experiment
are shown.
Table 2 Characteristics of antibodies used
Antibody Supplier/Company Methods of antigen retrieval AB dilution Conditions of incubation
Anti-AGE TransGenic Microwave 20 min 1:500 Overnight
(monoclonal mouse) Citrate buffer (pH6) 4 °C
Anti-RAGE R&D Microwave 20 min 1:500 Overnight
(polyclonal goat) Citrate buffer (pH6) 4 °C
Anti-Glyoxalase-I Santa Cruz Microwave 20 min 1:300 Overnight
(monoclonal mouse) Biotechnology Citrate buffer (pH6) 4 °C
Anti-Adiponectin Receptor Type 1 Phoenix Microwave 20 min 1:500 60 min
(polyclonal rabbit) Pharmaceuticals Citrate buffer (pH6) 4 °C
Anti-Adiponectin Receptor Type 2 Phoenix Microwave 20 min 1:500 Overnight
(polyclonal rabbit) Pharmaceuticals Citrate buffer (pH6) 4 °C
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Statistical analysis
AGE, RAGE, AdipoR1 and AdipoR2 were treated as
continuous variables. Associations with tumor stage,
grade and histological type were evaluated using non-
parametric tests, with correction for multiple compari-
sons (Bonferroni correction) when necessary (Mann
Whitney U test, Kruskal Wallis ANOVA, Spearman’s
correlation coefficient and Fischer’s exact test).
Survival analysis was performed using death due to
CRC as the end-point. The effect of various parameters
(age, sex, tumor location, stage, grade and AGE, RAGE,
AdipoR1 and AdipoR2 expression) on clinical outcome
was assessed by plotting survival curves according to the
Kaplan–Meier method and comparing groups using the
log rank test, as well as with multivariate analysis (Cox's
model). In survival analysis (univariate and multivariate),
continuous variables were categorized on the basis of re-
sults obtained from ROC (Receiver Operating Character-
istic) curves. Univariate survival analysis stratified by
TNM status was also performed for the examined
parameters, in order to adjust their effect on survival for
tumour stage. Multivariate survival models were
adjusted for those parameters that were proven to be
significant in univariate analysis, in order to evaluate
the predictive power of each parameter independently
of the others. Statistical calculations were performed
using the Statistical package STATA 11.0 for Win-
dows (Stata Corp., College Station, TX, USA). All
results with a two-sided p level ≤ 0.05 were considered
of marginal significance.
Fig. 1 AGE (aX20, bX10) and RAGE (c–f X20) immunoreactivity in CRC. Lower AGE expression is seen in a grade III (b) versus a grade II (a)
adenocarcinoma. RAGE expression is higher in tumoral tissue versus normal colonic mucosa (c) as well as in mucinous adenocarcinoma (d)
whereas low expression is depicted in a grade II adenocarcinoma (f)
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Validation cohort
An independent set of patients with CRC was used to
validate the chosen cut-off values for the expression of
GLO-I in univariate analysis. The results of univariate
survival analysis for GLO-1 expression in the population
group were used to calculate the required number of
patients in the validation group for an adequately pow-
ered analysis (80 %). In order to detect a Hazard ratio of
2.8836 as calculated in the patients’ group- using a two-
sided log-rank test and to achieve 80 % power at a 0.05
significance level, 47 patients would be needed.
The validation group we used consisted of 55 pa-
tients, the demographic data of whom are shown in
Table 1. Patients were diagnosed at the First Depart-
ment of Pathology, University of Athens, Medical
School, the Department of Pathology, “Tzaneio” Gen-
eral Hospital and the Department of Pathology,
“Agios Andreas” General Hospital and treated at
“Laikon” General Hospital, University of Athens,
“Tzaneio” General Hospital and “Agios Andreas” Gen-
eral Hospital, between 2010 and 2014.
Results
AGE and RAGE expression in normal colonic tissue,
colorectal adenocarcinomas and colon cell lines
AGE expression was observed in 122/124 examined
cases (98.39 %) with H-score ranging between 0 and 300
(median: 90). Accordingly, RAGE was expressed in all
but one cases (124/125, 99 %), with H-score ranging
between 0 and 285 (median: 100). Both molecules had a
diffuse cytoplasmic staining pattern (Fig. 1a–f ).
AGE and RAGE immunoreactivity in the adjacent nor-
mal colonic tissue was feasible in 89 cases for both anti-
bodies. Although there was no difference in the extent
of AGE and RAGE immunoexpression between normal
and neoplastic areas, the intensity of both AGE and
RAGE expression was higher in the tumoral tissue (p =
0.0001 for both relationships) Fig. 1c. Validation of the
immunohistochemical data by western immunoblotting
revealed that AGE and RAGE expression was higher in
CRC tissue compared to adjacent normal colon in the
two tested cases (Fig. 2).
Furthermore, western blot analysis of colon cancer cell
lines, SW480 colon adenocarcinoma, HT29 colon adeno-
carcinoma grade II, HCT116 colon carcinoma revealed
high protein expression of AGEs and RAGE (Fig. 2c).
Intriguingly, mucinous adenocarcinomas presented
marginally higher AGE expression (Mann–Whitney U
test, p = 0.0997, Fig. 1d). Moreover, AGE H-score was
correlated with tumor histological grade (Mann–Whit-
ney U test I vs II vs III, p = 0.0157, Fig. 1a, b and Fig. 3a,
Table 3), the lower levels being observed in grade II
cases. No correlations were observed between AGE or
RAGE and tumor stage or location (p > 0.10).
Fig. 2 Western immunoblot indicating AGEs, RAGE and GLO-I protein expression in two CRC and adjacent normal tissues a. The densitometric
quantification of AGEs and GLO-I expression (normalized to the actin levels) is shown in the graph b. Western immunoblot indicating AGEs, RAGE
and GLO-I protein expression in tree colon cancer cell lines SW480, HT29 and HCT116 c All experiments have been performed at least three times
and representative results of one experiment are shown
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GLO-I expression in normal colonic tissue, colorectal
adenocarcinomas and colon cancer cell lines
Cytoplasmic GLO-I expression (Fig. 4a–c) was observed
in 94.17 % of the examined cases (113/120). The median
H-score was 140 (range 0–300).
Normal adjacent colonic mucosa was mostly negative
for GLO-I, with 20 of the examined cases (20/91, 22 %)
being faintly to moderately positive (Fig. 4a). Further-
more, although it was unrelated to tumor histological
grade (p > 0.10), GLO-I expression was negatively
correlated with tumor T-category (Mann–Whitney U
test T1/T2 vs T3/T4, p = 0.0246, Fig. 3d, Table 3). Inves-
tigation of GLO-I expression by western immunoblot-
ting in normal and CRC samples, revealed higher
protein expression in tumor tissue (Figs. 2 and 4a). Simi-
larly, colon cancer cell lines revealed high GLO-I expres-
sion (Fig. 2c). An inverse relation between GLO-I and
AGE expression was clearly observed in normal colonic
mucosa and colon cancer cell lines, while it was less
evident in CRC tissue at both immunohistochemical and
western blot analysis.
Significant positive correlations emerged between
GLO-I and RAGE or Adipo1 H-score (Spearman’s cor-
relation coefficient, R = 0.2909, p = 0.0017 for the former
relationship and R = 0.4096, p = 0.0001 for the latter). On
the other hand, an inverse relationship emerged between
GLO-I and AGE, with increased levels of GLO-I H-
score (≥140) being correlated with lower AGE H-score
(Mann–Whitney U test, p = 0.0731), a relationship of
borderline significance however.
AdipoR1 and AdipoR2 expression in normal colonic tissue
and colorectal adenocarcinomas
AdipoR1 and AdipoR2 immunoreactivity was observed
in the majority of the examined cases (93/100, 93 % and
90/96, 93.7 % respectively). Both proteins had a wide
range of H-score (0–300, median value: 85 and 60 re-
spectively) and a cytoplasmic (Fig. 5a–f ), often granular
staining, more prominent near the luminal surface
(Fig. 5c).
The adjacent normal colonic tissue displayed margin-
ally more intense AdipoR1 expression when compared
Fig. 3 a Box plot illustrating the association of AGE expression with grade. b Box plot illustrating the inverse association of AdipoR1 H-score with
grade. c Box plot illustrating the inverse association of AdipoR2 H-score with grade. d Box plot illustrating the inverse association between GLO-I
immunoexpression and T-status. e Box plot illustrating the inverse association of AdipoR1 H-score with T-status
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to the neoplastic tissue in the 70 cases in which it could
be evaluated (Mann Whitney U test, p = 0.0530) (Fig. 5c).
On the contrary, there was no difference in AdipoR2
expression between the normal and neoplastic areas (the
former evaluated in 70 cases) (p > 0.10) (Fig. 5).
Mucinous adenocarcinomas had marginally higher
AdipoR1 and AdipoR2 expression levels (Mann–
Whitney U test, p = 0.0739 and 0.0993) (Fig. 5b, e).
Moreover, AdipoR1 H-score was negatively correlated
with tumor histological grade (Fig. 5a–d), (Kruskal Wal-
lis ANOVA, I vs II vs III, p = 0.0080, Fig. 3b, Table 3)
and T-category (Mann Whitney U test, T1/2 vs T3/4, p
= 0.0363, Fig. 3e). On the contrary, grade III tumors
tended to have higher levels of AdipoR2 expression
when compared to lower grades (I/II) [Mann Whitney
U test, p = 0.0210 (Fig. 3c). The correlations between
AdipoR1 or AdipoR2 and tumor TNM stage or loca-
tion were not significant (p > 0.10).
Survival analysis
Univariate survival analysis showed that advanced tumor
stage according to TNM status (I/II vs III/IV, p = 0.0001),
the presence of nodal (N) metastasis (p = 0.0005), the
presence of distant metastasis (M) (p = <0.0001), increased
AdipoR2 H-score (<60 vs ≥60) p = 0.0465, Fig. 6a), as well
as increased GLO-I H-score (300 vs <300, p = 0.0046,
Fig. 6d), were all correlated with shortened survival
(Table 4). Stratified survival analysis according to TNM
status showed that the effect of both AdipoR2 and GLO-I
on patients’ survival was significant in early stage tumours
(TNM stage I/II, p = 0.0002 for AdipoR2, Fig. 6b, and p =
0.0499 for GLO-I, Fig. 6e) in contrast to advanced stage
Table 3 Distribution of AdipoR1, AdipoR2, AGE, RAGE, GLO-I expression (%) and H-score among different groups of histological
grade, TNM status, T - category, Nodal metastasis status and histological type
AdipoR1 AdipoR2 AGE RAGE GLO-I
median (range) median (range) median (range) median (range) median (range)
Histological grade
I % 80 (10–90) 30 (10–95) 70 (20–100) 80 (30–100) 90 (5–100)
H-score 120 (10–270) 60 (10–237.5) 110 (35–250) 120 (30–255) 225 (10–300)
II % 40 (0–100) 40 (0–100) 50 (0–100) 65 (0–100) 70 (0–100)
H-score 60 (0–300) 45 (0–300) 80 (0–270) 100 (0–247.5) 136.25 (0–300)
III 7.5 (0–100) 80 (20–90) 70 (0–100) 80 (10–100) 100 (0–100)
8.75 (0–300) 90 (10–180) 120 (0–300) 100 (10–285) 200 (0–300)
TNM status
I/II % 55 (0–100) 40 (0–100) 60 (0–100) 75 (5–100) 80 (0–100)
H-score 60 (0–300) 57.5 (0–300) 90 (0–300) 112.5 (5–285) 140 (0–300)
III/IV % 60 (0–100) 65 (0–100) 60 (0–100) 60 (0–100) 70 (0–100)
H-score 105 (0–300) 60 (250) 83.75 (0–270) 90 (0–250) 132.5(0–300)
T-category
T1/T2 % 70 (10–90) 40 (20–95) 90 (10–250) 80 (0–100) 90 (20–100)
H-score 160 (10–270) 60 (30–237.5) 70 (10–100) 90 (0–200) 206.25(20–300)
T3/T4 % 45 (0–100) 50 (0–100) 90 (0–300) 70 (10–100) 70 (0–100)
H-score 55 (0–300) 60 (0–300) 60 (0–100) 105 (10–285) 120(0–300)
Nodal metastasis
Absent % 55 (0–100) 45 (0–100) 60(0–100) 80(5–100) 80(0–100)
H-score 75 (0–300) 70 (0–300) 90(0–300) 120(5–285) 140(0–300)
Present % 60 (0–100) 55 (0–100) 60(0–100) 60(0–100) 70 (0–100)
H-score 105 (0–300) 60 (0–250) 80(0–270) 90(0–250) 122.5(0–300)
Histological type
Mucinous % 80 (5–100) 70 (15–90) 60(0–100) 85(3–100) 95(10–100)
H-score 150 (5–300) 70 (12–180) 120(0–300) 120(60–285) 125 (15–300)
Non-mucinous % 50 (0–100) 40 (0–100) 60(0–100) 60(5–100) 75(0–100)
H-score 60 (0–300) 47.5 (0–300) 80(5–270) 100(5–250) 140(0–300)
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ones (TNM stage III/IV), in which both proteins failed to
retain their statistical significance (Fig. 6c, f ). AdipoR1,
AGE and RAGE did not add significant prognostic
information in this regard.
In multivariate survival analysis, after adjusting the
effect of GLO-I or AdipoR2 for TNM status in two
separate Cox regression models, this remained signifi-
cant, supporting a TNM-independent prognostic role for
both molecules (HR = 2.76, p = 0.010 for GLO-I and HR =
2.53, p = 0.050 for AdipoR2). Interestingly, in a multivari-
ate model including all three parameters that were proven
to be significant in univariate analysis (GLO-I, AdipoR2
Fig. 4 GLO-I immunoreactivity in CRC (aX10, bX10, cX20). Normal colonic mucosa is negative for GLO-I (a), whereas mucinous adenocarcinomas
display high GLO-I H-scores (b)
Fig. 5 AdipoR1 (a–d) and AdipoR2 (e, f) immunohistochemistry in CRC. Normal colonic mucosa is strongly positive for AdipoR1as opposed to
adjacent CRC (Note the cytoplasmic granular staining more prominent near the luminal surface) (c). Mucinous adenocarcinomas display high
levels of AdipoR1 (b) and AdipoR2 (e). Lower grade tumors display higher levels of AdipoR1 (d vs c). No difference is observed between normal
and CRC tissue for AdipoR2 expression (f). (aX20, bX20, cX20, dx20, eX20, fX10)
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and TNM status), GLO-I emerged as an independent pre-
dictor of adverse prognosis (HR = 2.98, p = 0.036), along
with TNM status (HR = 7.53, p < 0.0001).
Survival analysis-validation group
Univariate survival analysis in this group of patients
showed that overall survival was significantly lower in
the GLO-I low-expressor compared to the GLO-I high-
expressor group (H-score 300 vs <300, log-rank test, p <
0.0001, Fig. 7a). This effect remained significant in early
stage cases (TNM stage I/II, log-rank test p < 0.0001,
Fig. 7b), while it was of borderline significance in
advanced stage cases (TNM stage III/IV, log-rank test
p = 0.0527, Fig. 7c).
Discussion
The present cohort examined the immunohistochemical
localization of AGEs and their receptor RAGE expres-
sion in CRC versus adjacent non-tumoral tissue. Fur-
thermore, the expression of the detoxification enzyme
GLO-I and AdipoR1, AdipoR2 was also evaluated in an
attempt to reveal probable interrelations, associations
with clinicopathological characteristics or potential im-
pact on survival of CRC patients.
Previous studies in cancer cell lines and animal models
point towards the implication of the AGE-RAGE axis in
CRC development. Our western blot analysis in 3 colon
cancer cell lines reaffirms this notion, documenting an
increased expression of AGE and RAGE. Kuniyasu et al.
[12] first showed that RAGE was expressed in all exam-
ined CRC cell lines and its expression was associated
with in vitro cancer cell migration and invasion. In the
same study, cell treatment with AGE-bovine serum
albumin partially affected cell growth, migration and
invasion, implying a minimal direct role of AGEs in
CRC progression. In another survey, RAGE expression
was documented in Caco-2 human colon carcinoma cell
line, and treatment with AGE resulted in p44/42
(ERK1/2) MAP kinase activation in a time- and dose-
dependent manner [30]. Furthermore, Turovskaya et al. [31]
showed that RAGE promoted molecular tumor-stromal
interactions in a colitis-associated carcinogenesis mouse
model leading to colon tumor development. Similarly, it has
been hypothesized that RAGE acting synergistically with
the epithelial to mesenchymal transition pathway can
trigger the production of cancer stem cells [32].
Despite vigorous experimental research in the field, data
remain scarce regarding AGE and RAGE expression in
Fig. 6 Kaplan-Meier curves illustrating the adverse prognostic significance of AdipoR2 (a, b, c) and GLO-I (d, e, f) H-score in the whole population
cohort (a, d) as well as in early (b, e) and advanced stage (c, f) cases
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human normal versus tumorous colorectal epithelium. In
the present study, both AGE and RAGE tended to be
more intense in tumoral compared to non-tumoral epi-
thelium, also validated by western immunoblotting in two
normal and two cancerous tissues. In this context, Zill et
al. [30] observed RAGE expression in non-neoplastic
human intestinal tissues by RT-PCR. Kuniyasu et al. [33]
reported absence of RAGE mRNA in normal colon mu-
cosa in three examined cases. In the same study, immuno-
histochemical analysis of a large number of CRC samples
failed to reveal AGE positivity in the normal colonic mu-
cosa. The above inconsistencies may be attributed to vari-
ability of applied methodology and/or different antibodies
usage. However, further research is warranted to clarify
this issue. Notably, in an experimental survey by Heijmans
et al. [34], RAGE positivity was demonstrated throughout
the normal intestinal epithelium of the mice under study.
In our cohort, we found that AGE expression was as-
sociated to cancer histological grade, with lower levels
being observed in grade II cases. This finding suggests a
possible role during the early and late stages of
colorectal carcinogenesis. AGE expression has not been
previously reported to correlate with CRC grade. How-
ever, in gastric cancer patients, Kuniyasu et al. [35]
found RAGE positivity to be directly associated with
tumor grade. In our survey, AGE and RAGE were not
related to stage or any of its parameters, despite pre-
vious studies presenting a significant positive correl-
ation between RAGE and lymph node as well as
distant metastasis [33].
Regarding the endogenous detoxification enzyme of
AGEs, our immunohistochemical and western blot ana-
lysis are in agreement with previous reports showing
that GLO-I is more frequently expressed in CRC than
adjacent normal epithelium [16]. In addition, our results
confirmed the expected inverse relation between GLO-I
and AGE expression by western blotting in normal
colonic mucosa and colon cancer cell lines. However,
this relationship was not as clear in CRC tissue at both
the immunohistochemical and western blot level. These
findings overall recapitulate the attenuation of AGEs
cytotoxicity by the Glyoxalase scavenging system [13].
High GLO-I immunoreactivity cases also showed high
RAGE positivity, possibly reflecting an adaptation mech-
anism, with cancer cells exhibiting RAGE up-regulation
to overcome the GLO-I induced decrease of AGE levels.
The above findings attribute a significant role to the
AGE-RAGE-GLO-I system in CRC. In the present co-
hort, tumors with high GLO-I expression were more
frequently of low T category.
Furthermore, AdipoR1 and R2 were expressed both in
CRC and normal colonic mucosa. AdipoR1 immuno-
staining tended to be more intense in the latter, while no
significant difference was observed regarding the per-
centage of positive cells in neoplastic vs non-neoplastic
epithelium. In accordance with our findings, recent
surveys report AdipoR1 and R2 detection in cancerous
as well as normal colonic tissue, although there is
disagreement concerning the expression levels. Gialamas
et al. [21] and Williams et al. [24] using IHC, and Yama-
moto et al. [25] by performing RT-PCR, found a higher
expression of AdipoR1 and R2 in CRC than in normal
colonic epithelium [21, 24, 25]. On the contrary, in a
recent survey from Japan [23], AdipoR1 and R2 mRNA
levels were significantly lower in neoplastic tissue
compared to normal. Based on the above results, the au-
thors suggested that reduction of AdipoR permits cancer
cells to escape serum adiponectin tumor suppressive ef-
fects. Since it is difficult to explain the above differences,
larger prospective studies are required to comparatively
evaluate AdipoR1, R2 protein and mRNA expression in
normal, dysplastic and cancerous colon tissues.
In our cohort, AdipoR1 immunopositivity was in-
versely related to tumor histological grade and T cat-
egory, in agreement with previous reports [22].
Table 4 Results of univariate survival analysis regarding overall




< 70 vs ≥70 years >0.10
Gender
Male vs female >0.10
Histological type
non mucinous vs mucinous >0.10
Histological grade
I vs II vs III 0.0721
TNM stage
I vs II vs III vs IV 0.0001
Tumour status
T1-T2 vs T3-T4 >0.10
Nodal status
No vs N1 vs N2 0.0005
AdipoR1 H-score
< 85 vs ≥85 >0.10
AdipoR2 H-score
< 60 vs ≥60 0.0465
AGE H-score
< 90 vs ≥90 >0.10
RAGE H-score
< 100 vs ≥100 >0.10
GLO-I H-score
< 300 vs ≥300 0.0046
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Concurrent with these findings, a prognostic role of
serum adiponectin in CRC patients is suggested, since
this hormone’s concentration has been found to be
negatively correlated with CRC stage [18, 36], and a high
leptin/adiponectin ratio has been reported as a predictor
for adverse outcome [37]. Adiponectin serum levels were
also inversely related to CRC grade in one study [21].
On the contrary, in another report [38], the hormone’s
immunohistochemical expression by colon neoplastic
tissue showed a positive association with tumor grade.
Recent investigation in various cancer cell lines has
shown that adiponectin possesses both anti-proliferating
and pro-apoptotic effects [22, 39, 40]. Concerning CRC
cell lines, growth inhibition and apoptosis induction
after adiponectin treatment has been attributed to
MAPK/mTOR pathway activation [41, 42]. Moreover,
recent investigations have shown reduced AdipoR1 ex-
pression in tumors with lymph node metastasis [21, 23]
and venous invasion [25]. The above findings support
AdipoR1 overexpression as an early event in CRC
tumorigenesis, also suggesting a protective role against
tumor progression.
Regarding AdipoR2, we found a positive association
with grade. Grade III tumors showed higher levels of
expression than grade I/II, a finding in discordance to
Byeon et al. [22]. However, no significant relation to
stage or any staging parameters was observed. Interest-
ingly, literature regarding AdipoR2 and stage appears to
be controversial. One group presented a positive
correlation with T category and TNM stage [21],
whereas other investigators showed AdipoR2 to be in-
versely related to T category, N category, tumor stage
and lymphovascular invasion [22, 23]. Interestingly,
GLO-I was directly related to AdipoR2, while no associ-
ation with AdipoR1 was revealed.
We additionally examined the differential expression
of AdipoR1, AdipoR2, AGE, RAGE and GLO-I between
mucinous and non-mucinous tumours. We found a
trend towards higher expression of all these markers
except for Rage, in the subgroup of mucinous carcin-
omas which, although of borderline significance, seemed
to be more prominent for AdipoR1 and AGE. To our
knowledge, this is the first investigation of mucinous
CRC, as far as the above markers are concerned.
Finally, in the present cohort, survival analysis failed to
reveal AGE or RAGE as prognostic factors, in contrast
to an earlier report where Dukes’ B and C cases showed
a significantly poorer prognosis for RAGE positive pa-
tients [33]. Intriguingly, GLO-I expression was proven to
be an aggravating factor, even after adjustment for TNM
and AdipoR2, and despite the association with low T cat-
egory. These findings were validated in an independent
set of patients. After stage stratification, the prognostic
effect of GLO-I was maintained for early stages, for both
patient and validation cohorts, supporting a substantial
role of GLO-I in CRC progression, most probably asso-
ciated with cell detoxification from glycation by-
products, such as methylglyoxal. It seems that CRC
Fig. 7 Kaplan-Meier curves illustrating the adverse prognostic significance of GLO-I H-score in the entire validation cohort (a) as well as in early
(b) and advanced stage (c) cases
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overexpressing GLO-I gain an advantage by escaping
methylglyoxal-induced apoptosis resulting in tumor ag-
gressiveness and low patients survival rate. Considering
the recent glyoxalase inhibitors development [14], our
findings bring forward CRC as a potential candidate for
targeted therapy.
In addition, patients with high levels of AdipoR2 ex-
pression had a significantly shorter survival, which
remained after stage stratification for early stage pa-
tients, as well as in multivariate analysis. This finding
was somewhat expected since AdipoR2 immunoexpres-
sion was more prominent in grade III tumors. This is
the first study in which expression of Adiponectin recep-
tors is related to survival, as previous studies have failed
to demonstrate such a significant association [22]. Inter-
estingly, Baressi et al. [20] examined gastric cancer cases
and noted AdipoR1 positivity to be related to signifi-
cantly longer survival, although multivariate analysis did
not reveal AdipoR1 as an independent prognostic factor.
More extended surveys are needed to clarify the associ-
ation of adiponectin receptors with patient’s survival.
More importantly, our results point towards distinct
roles of AdipoR1 and R2 in CRC, relating the first one
with a favorable and the second with an aggressive
phenotype.
Conclusions
In the present study, we provide novel evidence regard-
ing the possible interactions between the components of
the AGE-RAGE axis, GLO-I and adiponectin receptors
in CRC. Interestingly, the examined molecules seem to
exert diverse roles in colorectal carcinogenesis, whereas
AdipoR2 and particularly GLO-I expression are intro-
duced as potential novel independent prognostic bio-
markers of adverse significance for patients with early
stage disease. Further studies are warranted to extend
our observations, as well as to investigate their potential
therapeutic significance.
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